Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Bailard Inc.

Bailard Inc. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 69.9% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,034 shares of the biopharmaceutical company's stock after selling 9,388 shares during the quarter. Bailard Inc.'s holdings in Regeneron Pharmaceuticals were worth $2,558,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $802,036,000. GAMMA Investing LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its position in Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Robert W. Baird lowered their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. Finally, Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $550.00 on Friday. The stock's 50-day simple moving average is $544.14 and its 200 day simple moving average is $616.16. The stock has a market capitalization of $59.38 billion, a price-to-earnings ratio of 14.00, a price-to-earnings-growth ratio of 2.03 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter last year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.